Psilocybin: all studies (page 102) - The Consciousness Library

Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.

Scientific Reports March 26, 2024 Berit Singer, Daniel Meling, Matthias Hirsch-Hoffmann et al. 15 citations

In this study, for the first time, we explored a dataset of functional magnetic resonance images collected during focused attention and open monitoring meditation before and after a five-day psilocybin-assisted meditation retreat using a recently established approach, based on the Mapper algorithm from topological data analysis. After generating subject-specific maps for two groups (psilocybin...

DOI: 10.1038/s41598-024-55726-x Full text Meditation Psychedelics Consciousness Self-awareness

Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression

Journal of Psychopharmacology March 22, 2024 Tommaso Barba, David Erritzøe, Meg J. Spriggs et al. 26 citations

Background: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in...

DOI: 10.1177/02698811241237870 Psilocybin Major depressive disorder Escitalopram Discontinuation +2

Problems of Qualification of Trafficking in Plants and Plant Parts Containing Psychoactive Substances and Mushrooms Containing Psilocybin and (or) Psilocin

Drug control March 14, 2024 Aleksandr V. Kulikov, Ilya Yu. Zheleznyak

Purpose: research of such items of illicit drug trafficking as plants and plant parts containing psychoactive substances. Methodology: study and analysis of judicial practice of higher courts and scientific research of natural science specialists; formal legal and technical legal methods. Conclusions: there is a lack of due attention to the problem of selling narcotic plants and their parts, as...

DOI: 10.18572/2072-4160-2024-1-23-26 Psilocybin Psychoactive substance Hallucinogen

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

PLoS One March 14, 2024 Adam W. Levin, Rafaelle Lancelotta, Nathan D. Sepeda et al. 65 citations

We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression outcomes. In a randomized, waiting list-controlled clinical trial for major depressive disorder in adults ( N = 24), participants were...

DOI: 10.1371/journal.pone.0300501 Psychedelic therapy Psilocybin research Therapeutic relationships Mental health +1

New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.

Med March 8, 2024 Scott T Aaronson, Zofia Kozak 1 citation

Psilocybin has demonstrated efficacy for treating depression; however, psychiatrically complex patients have been excluded from trials. A recent clinical trial by Rosenblat at al.1 demonstrates feasibility of a flexible dosing schedule of psilocybin in individuals with severely treatment-resistant depression (TRD), including those with co-morbid conditions or bipolar II disorder (BPII),...

DOI: 10.1016/j.medj.2024.01.014 Full text Treatment-resistant depression Psychedelic therapy Personalized medicine Depression treatment +1

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.

Med March 8, 2024 Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle et al. 97 citations

Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations. Our aim was to determine the feasibility of PAP in a complex population, including high levels of treatment resistance in major depressive and bipolar disorder and patients with baseline suicidality and significant comorbidity....

DOI: 10.1016/j.medj.2024.01.005 Full text Major depressive disorder Treatment-resistant depression Psychedelic therapy Translation to patients +11

Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

International Journal of Mental Health and Addiction March 7, 2024 Brandon Weiss, Leor Roseman, Bruna Giribaldi et al. 26 citations

Abstract The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether...

DOI: 10.1007/s11469-024-01253-9 Full text Major depressive disorder Mystical experience Ego dissolution Psilocybin therapy psilocybin +7

Patients with bipolar II disorder benefit from single dose of psilocybin

The Brown University Psychopharmacology Update March 4, 2024

A single 25‐mg dose of psilocybin resulted in improvement in depressive symptoms in all 15 participants in an open‐label nonrandomized trial enrolling adults with bipolar II disorder. Twelve of the 15 participants met response and remission criteria at the study's 12‐week endpoint.

DOI: 10.1002/pu.31143 Psilocybin Bipolar disorder Pharmacology Hallucinogen +1

Psilocybin with Acceptance and Commitment Therapy (ACT) for the Treatment of Social Anxiety Disorder (SAD)

March 1, 2024 Aspen Allred, Aspen Allred

Social Anxiety Disorder (SAD) is a debilitating mental health condition characterized by an overwhelming fear and anxiety of social rejection that can lead to chronic patterns of social behavioral avoidance. Despite the existence of traditional efficacious treatments, a significant number of individuals either do not respond to treatment or experience a recurrence of symptoms over extended...

DOI: 10.15760/honors.1468 Full text Psilocybin Biopsychosocial model Social anxiety Psychotherapist +3

Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent

BMJ Case Reports March 1, 2024 Clarice Ho, John R. Crawford

A previously healthy adolescent presented to the emergency department with an abrupt onset of altered mental status and abnormal behaviour, including shaking of the extremities, rocking back and forth, and non-sensical speech, after ingestion of chocolate that contained psilocybin. Neurological

DOI: 10.1136/bcr-2024-259721 Psilocybin Toxic encephalopathy Hallucinogen Ingestion +3

Research